Clinical trials: Solid Tumor (Phase I)
Solid Tumor
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
The study is being conducted to evaluate the safety and tolerability of SHR-4595 for injection in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and…
- Trial name
- NCT07830199
- Testing
- SHR-4595 for Injection
- Where
- 2 sites in China
- Volunteers
- 208 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Locally Advanced Unresectable Carcinoma
A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors
This is a multi-center, open-label, dose escalation and expansion, phase I study to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) characteristics, preliminary efficacy of SYHA1815 in…
- Trial name
- NCT05105464
- Testing
- SYHA1815
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Advanced Solid Tumor
Study of ZGGS18 in Patients With Advanced Solid Tumors
A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors
- Trial name
- NCT05584800
- Testing
- ZGGS18 for Injection
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Pediatric Cancer, Solid Tumor Pediatric
Durvalumab and Tremelimumab for Pediatric Malignancies
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the…
- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Trial name
- NCT03837899
- Testing
- Durvalumab / Tremelimumab Combination Therapy
- Where
- 19 sites in United States, France and 5 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Advanced Breast Cancer
Study of DM5167 in Patients With Advanced Solid Tumors
DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety.
- Trial name
- NCT07101601
- Testing
- DM5167
- Where
- 4 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- DIGMBIO
Cancer, Neoplasm Metastasis
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
- Trial name
- NCT00492830
- Testing
- TRC093 recombinant humanized IgG1k monoclonal antibody
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Solid Cancers
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer
This study is for subjects with solid cancers (gastrointestinal, lung, breast, prostate, lymphoma or cancer of the lymph nodes).
- Trial name
- NCT01820299
- Testing
- Grape Seed Extract, Vitamin D
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medical University of South Carolina
Solid Tumor, Colorectal Cancer
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
This will be a Phase 1, open-label study of DS-7423 to assess its safety and tolerability, identify a RP2D, (recommended Phase 2 Dose) and assess its Pharmacokinetics (PK) (what your body does to process the drugs and how your…
- Conditions
- Solid Tumor, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01364844
- Testing
- DS-7423
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumors
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
- Trial name
- WEE1 (NCT04768868)
- Testing
- IMP7068
- Where
- 16 sites in United States, China and 1 more
- Volunteers
- 350 people
- Sponsor
- Impact Therapeutics, Inc.
Metastatic Cancer, Solid Tumor
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03311412
- Testing
- Sym021, Sym022, Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 89 people
- Sponsor
- Symphogen A/S
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
Breast Cancer, Advanced Malignant Solid Tumors
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information…
- Trial name
- NCT00706030
- Testing
- neratinib, vinorelbine
- Where
- 35 sites in United States, Belgium and 9 more
- Volunteers
- 92 people
- Sponsor
- Puma Biotechnology, Inc.
Solid Tumor
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
The main purpose of the dose escalation phase of the study is to determine the safety of different doses of OMX-0407. The dose expansion (phase Ib) part of the study will evaluate efficacy, safety and tolerability at a dose…
- Trial name
- NCT05826600
- Testing
- OMX-0407
- Where
- 24 sites in Belgium, France and 1 more
- Volunteers
- 68 people
- Sponsor
- iOmx Therapeutics AG
Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Open-label, multicentre, dose-escalation Phase I/II study to evaluate safety, efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with doxorubicin administered q 3 weeks in patients with advanced solid…
- Trial name
- NCT00878800
- Testing
- PXD101, Doxorubicin
- Where
- 3 sites in Denmark, United Kingdom
- Volunteers
- 41 people
- Sponsor
- Valerio Therapeutics
Solid Tumor
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
- Trial name
- NCT04158336
- Testing
- Azenosertib
- Where
- 8 sites in United States
- Volunteers
- 274 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumours
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
- Trial name
- TEADES (NCT06725758)
- Testing
- ODM-212
- Where
- 20 sites in United States, Finland and 4 more
- Volunteers
- 315 people
- Sponsor
- Orion Corporation, Orion Pharma
Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors
This is a multicenter, open-label, safety run-in, dose-expansion and cohort-expansion Phase I/II study designed to evaluate the safety, tolerability, PK profile and preliminary anti-tumor efficacy of SYS6043 (a B7-H3-targeted…
- Trial name
- NCT07833735
- Testing
- SYS6043, bevacizumab, carboplatin
- Volunteers
- 400 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
- Trial name
- NCT04689100
- Testing
- JMT101
- Where
- 9 sites in China
- Volunteers
- 259 people
- Sponsor
- Shanghai JMT-Bio Inc.